Range Cancer Therapeutics Index ETF

Shareclass
Range Cancer Therapeutics ETF (CNCR)
Type
Exchange-traded fund
Gender equality score
Gender equality score

42
/ 100 points
Overall score
Average Equileap Gender Equality Score of fund holdings, weighted by market value
Peer rank
Group ranking

F
7
percentile

Universe: Groups

Group: Sector Equity Funds

Ranking: 807 out of 867 funds


See more funds from this group
 All funds
 Groups
 Categories
Gender balance in leadership and workforce
Gender balance in leadership and workforce
25/40
See the score criteria
Equal compensation and work life balance
Equal compensation and work life balance
6/30
See the score criteria
Policies promoting gender equality
Policies promoting gender equality
12/20
See the score criteria
Commitment, transparency, and accountability
Commitment, transparency, and accountability
0/10
See the score criteria
Top scoring holdings
Top scoring holdings
The top 10 holdings in this portfolio with the best scores on the Equileap Gender Scorecard. In the case of ties, the holding with more assets invested is listed higher.
  • 1. Bristol-Myers Squibb Co
    1.36% of assets
    $106,575 invested
  • 2. Merck & Co Inc
    1.46% of assets
    $114,509 invested
  • 3. HUTCHMED (China) Ltd ADR
    1.59% of assets
    $124,948 invested
  • 4. Regeneron Pharmaceuticals Inc
    1.44% of assets
    $112,567 invested
  • 5. BioNTech SE ADR
    1.68% of assets
    $131,541 invested
  • 6. Recursion Pharmaceuticals Inc Class A
    1.33% of assets
    $104,108 invested
  • 7. Genmab AS ADR
    1.65% of assets
    $129,523 invested
  • 8. Arcellx Inc
    1.45% of assets
    $113,727 invested
  • 9. Iovance Biotherapeutics Inc
    1.56% of assets
    $122,279 invested
  • 10. Schrodinger Inc Ordinary Shares
    1.76% of assets
    $137,582 invested
Bottom scoring holdings
Bottom scoring holdings
The bottom 10 holdings in this portfolio with the worst scores on the Equileap Gender Scorecard. In the case of ties, the holding with more assets invested is listed higher.
  • 1. SpringWorks Therapeutics Inc Ordinary Shares
    1.51% of assets
    $118,343 invested
  • 2. Nuvalent Inc Class A
    1.62% of assets
    $126,944 invested
  • 3. Kymera Therapeutics Inc Ordinary Shares
    1.61% of assets
    $126,559 invested
  • 4. Revolution Medicines Inc Ordinary Shares
    1.68% of assets
    $131,437 invested
  • 5. Arvinas Inc
    1.8% of assets
    $140,856 invested
  • 6. Xencor Inc
    1.38% of assets
    $108,150 invested
  • 7. Ginkgo Bioworks Holdings Inc
    1.54% of assets
    $120,831 invested
  • 8. Legend Biotech Corp ADR
    1.5% of assets
    $117,362 invested
  • 9. Merus NV
    1.57% of assets
    $122,786 invested
  • 10. Blueprint Medicines Corp
    1.58% of assets
    $123,778 invested
Find sustainably-invested mutual funds and ETFs



Search for funds from your 401(k), retirement plan, or personal portfolio
Financial performance
Performance data provided byMorningstarFind more financial data on CNCR at Morningstar.com
Gender Equality and Returns
Returns chart for Range Cancer Therapeutics Index ETF
Enlarge
The figure above charts annualized returns and Gender Equality Fund grades. The orange marker represents this fund. The purple marker (if present) represents an assigned benchmark. Blue dots represent funds in the same Morningstar category as this fund. Dark gray dots represent funds in the same grading group as this fund. Returns are for the most recent available for this fund of 1, 3, 5, or 10 year annualized returns. The higher a fund is marked on the Y axis, the better its returns for the specified time period. The higher a fund is marked on the X axis, the better its Gender Equality Funds group ranking. Read more on the How it Works page.
Benchmarking tool
Current fund
CNCR
Range Cancer Therapeutics Index ETF
Family
Range Cancer
Category
Health
vs.
Benchmark
ACWI
iShares MSCI ACWI ETF
Family
iShares from BlackRock
Category
Global Large-Stock Blend
Fund comparison settings
Investment timeline
Performance as of: 4/30/25
1 year
3 years
5 years
10 years
Benchmark
Suggested: MSCI ACWI
ACWI - iShares MSCI ACWI ETF
Fund comparison results
Compared to the benchmark, this fund has:
Lower 5-yr returns 
27% less  in annualized returns
Lower overall gender equality score 
13 / 100 points lower
Lower gender balance in leadership and workforce score 
1 / 40 points lower
Lower equal compensation and work life balance score 
4 / 30 points lower
Lower policies promoting gender equality score 
6 / 20 points lower
Lower commitment, transparency, and accountability score 
1 / 10 points lower
Current fund
CNCR
Range Cancer Therapeutics Index ETF
Family
Range Cancer
Category
Health
vs.
Benchmark
ACWI
iShares MSCI ACWI ETF
Family
iShares from BlackRock
Category
Global Large-Stock Blend
Fund comparison settings
Investment timeline
Performance as of: 4/30/25
1 year
3 years
5 years
10 years
Benchmark
Suggested: MSCI ACWI
ACWI - iShares MSCI ACWI ETF
Fund comparison results
Compared to the benchmark, this fund has:
Lower 5-yr returns 
27% less  in annualized returns
Lower overall gender equality score 
13 / 100 points lower
Lower gender balance in leadership and workforce score 
1 / 40 points lower
Lower equal compensation and work life balance score 
4 / 30 points lower
Lower policies promoting gender equality score 
6 / 20 points lower
Lower commitment, transparency, and accountability score 
1 / 10 points lower
Current fund
CNCR
Range Cancer Therapeutics Index ETF
Family
Range Cancer
Category
Health
vs.
Benchmark
ACWI
iShares MSCI ACWI ETF
Family
iShares from BlackRock
Category
Global Large-Stock Blend
Fund comparison settings
Investment timeline
Performance as of: 4/30/25
1 year
3 years
5 years
10 years
Benchmark
Suggested: MSCI ACWI
ACWI - iShares MSCI ACWI ETF
Fund comparison results
Compared to the benchmark, this fund has:
Lower 5-yr returns 
27% less  in annualized returns
Lower overall gender equality score 
13 / 100 points lower
Lower gender balance in leadership and workforce score 
1 / 40 points lower
Lower equal compensation and work life balance score 
4 / 30 points lower
Lower policies promoting gender equality score 
6 / 20 points lower
Lower commitment, transparency, and accountability score 
1 / 10 points lower
Month-end trailing returns  
Annualized returns
Gender-lens analysis
1-yr
3-yr
5-yr
10-yr
Overall gender equality score
This fund
CNCR - Range Cancer Therapeutics Index ETF
-32.21%
-13.47%
-13.6%
/
42  / 100 points
Benchmark
ACWI - iShares MSCI ACWI ETF
12%
10%
13%
8.76%
55  / 100 points
Fund compared to benchmark
 
-44.4%
-23.93%
-26.73%
/
13  / 100 points lower
Find more financial data on CNCR at Morningstar.com
What's next?
Learn how to make a change and move your money
Get started with our action toolkit
Ask your employer about gender-lens investing in your retirement plan
Find socially responsible funds that invest in gender equality
Learn more about As You Sow's Invest Your Values program
Visit Fossil Free Funds to measure the climate risk of this portfolio
More from Invest Your Values
See how mutual funds and ETFs are rated on issues ranging from fossil fuels, to deforestation, gender equality, guns, prisons, weapons, and tobacco

Disclaimer: As You Sow is not an investment adviser

As You Sow is not an investment adviser as that term is defined under federal and state (California) laws and regulations. As You Sow is a tax-exempt, nonprofit organization dedicated to educating and empowering shareholders to change corporations for the good through the collection, analysis and dissemination of relevant information to the public, free of charge. As You Sow does not provide financial planning, legal or tax advice. Nothing on this website shall constitute or be construed as an offering of financial instruments, or as investment advice or investment recommendations.
See our full disclaimer